lestaurtinib has been researched along with Metastase in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carducci, MA; Collins, C; Denmeade, SR; Eisenberger, MA; Isaacs, JT; Partin, AW; Pili, R; Sinibaldi, VJ; Walczak, JS | 1 |
| Dalrymple, SL; Denmeade, SR; Dionne, CA; Isaacs, JT; Lamb, JC; Miknyoczki, S; Weeraratna, AT | 1 |
2 other study(ies) available for lestaurtinib and Metastase
| Article | Year |
|---|---|
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Topics: 3T3 Cells; Aged; Aged, 80 and over; Animals; Carbazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Furans; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors | 2007 |
Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Carbazoles; Cell Division; Cell Line; Disease Models, Animal; Furans; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Receptor, trkA; Survival Analysis; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |